A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

NCT02533453 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

BIOLOGICAL: Bydureon

Sponsor

AstraZeneca